558Background: Genomic platforms, such as Mammaprint (Agendia) (MP) and OncoType (Genomic Health) (OT), have been validated to determine the risk of relapse in therapeutic decision-making in early-... Click to show full abstract
558Background: Genomic platforms, such as Mammaprint (Agendia) (MP) and OncoType (Genomic Health) (OT), have been validated to determine the risk of relapse in therapeutic decision-making in early-...
Keywords:
mamapred new;
risk;
innovative approach;
approach determine;
determine;
new innovative
Journal Title: Journal of Clinical Oncology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!